Compare Stocks → Elon Musk’s warning to America (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:JAGXNASDAQ:SVRANASDAQ:TLGT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsJAGXJaguar Health$0.09+23.3%$0.08$0.05▼$1.22$4.56M1.3179.55 million shs61.88 million shsSVRASavara$4.98+2.7%$4.94$1.63▼$5.70$687.99M0.77768,766 shs904,349 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%JAGXJaguar Health+23.32%+13.80%+55.27%-40.62%-87.79%SVRASavara+2.68%+1.84%-6.04%+5.96%+145.32%TLGTTeligent0.00%0.00%0.00%0.00%0.00%Your Money is Not Safe (Ad)Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOWMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Health0.1061 of 5 stars0.02.00.00.02.60.00.6SVRASavara1.6815 of 5 stars3.51.00.00.02.61.70.6TLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ASVRASavara3.00Buy$8.2064.66% UpsideTLGTTeligentN/AN/AN/AN/ACurrent Analyst RatingsLatest SVRA, TLGT, JAGX, and CLSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00JAGXJaguar Health$11.96M0.38N/AN/A($0.32) per share-0.28SVRASavaraN/AN/AN/AN/A$1.04 per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AJAGXJaguar Health-$47.45MN/A0.00N/AN/A-370.40%-1,191.67%-79.95%4/1/2024 (Confirmed)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)TLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest SVRA, TLGT, JAGX, and CLSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/A 3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52JAGXJaguar Health22.001.771.10SVRASavara0.1915.6615.66TLGTTeligentN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%JAGXJaguar Health12.04%SVRASavara87.93%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipCLSNImunon4.66%JAGXJaguar Health0.16%SVRASavara4.58%TLGTTeligent0.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableJAGXJaguar Health6050.76 million50.68 millionNo DataSVRASavaraN/A138.15 million131.82 millionOptionableTLGTTeligent2,357N/AN/AOptionableSVRA, TLGT, JAGX, and CLSN HeadlinesSourceHeadlineTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’charlotteobserver.com - June 7 at 10:18 AMβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzznews.google.com - May 13 at 1:32 AMLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan Newsnews.google.com - May 13 at 1:32 AMGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Todaynews.google.com - May 11 at 4:41 AMGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examinernews.google.com - May 8 at 10:54 AMDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journalnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examinernews.google.com - May 5 at 9:12 AMEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journalnews.google.com - May 3 at 7:08 AMErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journalnews.google.com - May 2 at 8:42 AMFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journalnews.google.com - April 29 at 8:17 AMTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRnews.google.com - April 28 at 10:17 PMDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRnews.google.com - April 26 at 1:32 PMTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRnews.google.com - April 26 at 8:32 AMTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan Newsnews.google.com - April 24 at 4:23 PMIDT Corp. Cl Bwsj.com - April 23 at 2:59 AMMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journalnews.google.com - April 17 at 2:17 PMHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletinnews.google.com - April 12 at 1:13 PMMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journalnews.google.com - April 10 at 1:16 PMEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globenews.google.com - April 6 at 1:58 PMLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journalnews.google.com - March 29 at 7:08 AMMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journalnews.google.com - March 29 at 2:07 AMGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRnews.google.com - March 28 at 10:26 AMBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supranews.google.com - March 25 at 8:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.